Related Experiment Video
Updated: Jul 8, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Drug-eluting stents: a critique
1Cardiovascular Centre Aalst, OLV Ziekenhuis, Moorselbaan 164, 9300 Aalst, Belgium.
Heart (British Cardiac Society)
|January 16, 2008
Summary
Drug-eluting stents (DES) effectively reduce restenosis after coronary angioplasty. However, recent data suggest potential safety concerns, including increased late stent thrombosis, warranting careful consideration of their net benefit.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Background:
- Restenosis remains a significant complication of coronary angioplasty.
- Drug-eluting stents (DES) have shown substantial efficacy in reducing restenosis rates.
- Widespread adoption of DES has led to off-label use in high-risk patients.
Purpose of the Study:
- To critically review the efficacy and safety data of drug-eluting stents.
- To discuss factors influencing the current clinical practice and perceived value of DES.
- To address emerging concerns regarding long-term DES safety.
Main Methods:
- Systematic review of randomized controlled trials and observational studies.
- Analysis of medium- to long-term follow-up data on DES.
- Critical appraisal of efficacy and safety outcomes, including restenosis and stent thrombosis.
Main Results:
- DES significantly reduce restenosis by 60-75% in various patient and lesion subsets.
- Emerging data indicate an increased risk of late stent thrombosis with DES.
- Mechanisms underlying DES-associated stent thrombosis require further elucidation.
Conclusions:
- While DES offer significant restenosis reduction, concerns regarding late stent thrombosis necessitate careful risk-benefit assessment.
- The expanding use of DES, including off-label applications, requires ongoing safety surveillance.
- Further research is needed to clarify the mechanisms of stent thrombosis and optimize DES utilization.
